IMV Inc
Halifax
About IMV Inc
IMV Inc Inc. applies its novel adjuvanting platform to the development of vaccines for cancer therapy, infectious diseases and animal health. The Company’s DepoVax™ platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. IMV Inc has advanced two DepoVax-based cancer vaccines into Phase I human clinical trials. The Company is also advancing a broad infectious disease pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the Company’s human health vaccine strategy, it continues to capture value from animal health vaccine applications. IMV Inc has key partnerships in the animal health sector including an agreement with Pfizer Animal Health.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $71.2M
- Funding stage: IPO
- Last round: Post-IPO Debt (Dec 2021)
- Ticker: cve:IMV
- Website: imvaccine.com
- Phone: 19024920888
Industries & Categories
Biotechnology, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/imv-inc-164266 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.